The company's diagnostic device uses medical-grade components like a probe, scanner, tower, monitor, and keyboard to assess the risk of malignancy in lung nodules found in the chest. By analyzing computed tomography scans, doctors can detect lung cancer early and start treatment. ProLung is a leader in predictive analytics technology and non-invasive biomarkers for lung cancer risk stratification. Their solutions aim to shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. While their predictive analytics platform is approved for sale in the European Economic Area, it is currently only available for investigational use in the US. IONIQ, another company, aims to improve the cancer landscape by developing a modern solution for the early detection of multiple cancers. Their goal is to expand the therapeutic window, improve survivability, and reduce healthcare costs.